Clinical Research Support | Departments | Trials | Frequently Asked Questions | Request Trial Information
Evaluate a smoking cessation intervention among cancer patients [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
Evaluate a smoking cessation intervention among cancer patients who are scheduled to receive or currently receiving surgery, radiation or chemotherapy OR have received one or more of the following within the last 6 months surgery, last radiation treatment, or last chemotherapy treatment in a community outpatient setting.
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Ochsner accepts all major insurances.
Ochsner is a 501(c)3 not-for-profit organization, founded on providing the best patient care, research, and education.
We are one of the country’s largest non-university based academic medical centers.